
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc. demonstrates a positive outlook due to the promising efficacy of its pipeline, particularly with binimetinib and VS-7375, which show enhanced response rates and strong physician support in both academic and community oncology settings. The company's focus on combining treatments has the potential to improve patient outcomes, as demonstrated by advanced results in non-small cell lung cancer (NSCLC) and the KRAS G12D landscape, which is pivotal for expanding their market share. Additionally, the lower treatment discontinuation rates compared to historical MEK inhibitors further solidify Verastem's position as a credible contender in the competitive oncology sector, suggesting a strong foundation for sustained growth.
Bears say
Verastem Inc has consistently reported operating losses since its founding and may require several years to achieve profitability, indicating significant financial challenges ahead. The company's focus on KRAS inhibitors faces hurdles due to lower overall response rates in certain patient populations, particularly evident in colorectal cancer, which may hinder market acceptance and revenue generation. Additionally, potential delays in regulatory approvals for their treatments could further depress the company’s stock value, reflecting ongoing uncertainties in their clinical and commercial prospects.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares